labeled tracer in tumor, the following points should arouse attention, which could also be considered as the new findings and contributions of this study to the field of the tumor imaging agents: (1) the F-18 labeled tumor radiotracers which have closer interaction with the FAK, should be further designed, via building of models such as 3D-QSAR model to make reasonable guidance to our drug design and consideration of some functional groups which have hydrogen-bonding or salt-bridge interactions with key residues in the kinase domain of FAK; (2) the F-18 radiotracers with better pharmacokinetic properties should be designed, via building of dynamic drug absorption and distribution model in different tissues, to predict whether the molecules have ideal absorption in tumor and low uptake in non-target tissues. The relevant study is being undertaken.
Preparation, in vitro and in vivo evaluation, and molecular dynamics (MD) simulation studies of novel F-18 labeled tumor imaging agents targeting focal adhesion kinase (FAK) † simulations and the docking studies were in consistent with the changing trends of the interaction between the F-19 standards and the FAK. Finally, in order to further increase the uptake of the F-18 labeled tracer in tumor, the following points should arouse attention, which could also be considered as the new findings and contributions of this study to the field of the tumor imaging agents: (1) the F-18 labeled tumor radiotracers which have closer interaction with the FAK, should be further designed, via building of models such as 3D-QSAR model to make reasonable guidance to our drug design and consideration of some functional groups which have hydrogen-bonding or salt-bridge interactions with key residues in the kinase domain of FAK; (2) the F-18 radiotracers with better pharmacokinetic properties should be designed, via building of dynamic drug absorption and distribution model in different tissues, to predict whether the molecules have ideal absorption in tumor and low uptake in non-target tissues. The relevant study is being undertaken.
Introduction
Functional molecular imaging on the basis of radiotracers (imaging agents), has facilitated the diagnosis and management of illnesses such as cancer, heart diseases and brain disorders. PET/CT and SPECT/CT based on the radiotracers are subelds of nuclear imaging. They can identify disease state at an early stage of development of disease, oen before symptoms occur or abnormalities can be detected with other tests such as X-ray, NMR and CT. Among them, PET/CT based on the positron isotope (such as F-18) labeled radiotracers, is the most sensitive imaging method recognized by modern medical eld, which is of great signi-cance for the early diagnosis, staging, prognosis judgment and treatment plan of cancer. PET/CT on the basis of 18 F-FDG is most widely used in clinical diagnosis and evaluation of cancer. However, this kind of radiotracer has fatal drawbacks. For example, its high accumulation in inammed and infected tissues can lead to false-positive results and its low uptake in tumors that are growing slowly can cause false-negative results. Therefore, there is an urgent need to develop new PET radiotracers with obvious targeting and tissue specicity for tumor. Focal Adhesion Kinase (FAK), a kind of non-receptor tyrosine kinase, 1,2 has been considered to be a pivotal pathogenic mediator of various diseases. Among them, cancer is the most widely studied disease.
3 Many evidence has suggested that FAK participates in a variety of biological behaviors of tumor, with its over-expression or high expression in the vast majority of types of tumor cells. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] In addition, FAK over-expression or high expression has been shown to be correlated with worse outcome in most kinds of cancer patients with hepatocellular carcinoma, invasive breast carcinoma, intestinal-type gastric carcinoma, endometric cancer, acute myeloid leukemia, anaplastic astrocytoma tumor, sarcoma (such as osteosarcoma), ovarian carcinoma, neuroblastoma, thyroid cancer, prostate cancer, head and neck squamous cell carcinoma and so on.
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Therefore, people have developed many FAK inhibitors as anti-neoplastic drugs, among which some even in clinical phase II trial. By and large, small molecular FAK inhibitors fall into two categories: 20, 22, 23 inhibitors which bind to the ATP-binding site, 4, 5, [24] [25] [26] [27] [28] and inhibitors targeting the scaffolding function of FAK.
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However, as far as we know, most of all of the previous studies were just focused on the research of FAK inhibitors for the tumor therapy at the level of generic pharmaceuticals, except for the only two recent reports by our research group which were rst dedicated to the development of FAK-targeted radiotracers for tumor imaging on the radiopharmaceutical level. 22, 23 In this work, we obtained another two F-18 labeled novel 5-bromo-N 2 -(4-(2-uoro-pegylated (FPEG))phenyl)-N 4 -(4-methoxy-phenyl)-pyrimidine-2,4-diamine analogues and evaluated them as tumor imaging agents targeting FAK, in order to make some comparison with our previous work in the bioactivity of the radiotracers, where the le side chain of the target compounds changed from "4-(2-uoro-pegylated (FPEG))-3,5-dimethoxyphenyl" in one of our previous reports 22 to "4-(2-uoro-pegylated (FPEG))phenyl", and the FPEG chain on the le side of the target compounds changed from n ¼ 1 in another one of our previous reports 23 to n ¼ 2 & n ¼ 3 here.
Experimental

General remarks
All chemicals and reagents used in the study (including 4 and 6a-6b) were of commercial quality and were used as purchased. Cartridge, 37-55 mm particle size) with 1 N NaHCO 3 (10 mL), followed by deionized water (10 mL), and the Waters Sep-Pak® C18 Plus Light Cartridges (130 mg Sorbent per Cartridge, 55-105 mm particle size) with methanol (10 mL) and deionized water (10 mL) before use. Radiopharmaceuticals were puried and their radiochemical purity were determined on a Shimadzu® LC-20AT HPLC apparatus equipped with a SPD-20A UV detector (l ¼ 254 nm) and Bioscan® ow count 3200 NaI/PMT g-radiation scintillation detector. We performed the radiopharmaceutical HPLC separations on a Inertsil® ODS-3 C18 reverse phase semi-preparative column (GL Sciences, Inc. 5 mm, 10 mm Â 250 mm), and we carried out the elution with a binary gradient system at a ow rate of 2.0 mL min À1 . Their radiochemical purity determination were achieved on a Kromasil® 100-5C18 reverse phase column (AkzoNobel, 5 mm, 4.6 mm Â 250 mm), and elution was with a binary gradient system at a ow rate of 2.0 mL min À1 .
We purchased S180 ascites sarcoma mice from Beijing Vitalriver Animal Technology Co., Ltd., and Beijing Xinglong Animal Technology Co., Ltd. provided normal ICR mice (20-25 g, female) . The measurement of the F-18 radioactivity of the tissues and organs of interest was performed on a PerkinElmer® 2480 WIZARD 2 automatic g-counter. The
Micro-PET imaging was performed on a Siemens Inveon DPET 120. All protocols requiring the use of mice were approved by the Animal Care Committee of Beijing Normal University.
Synthesis
2.2.1. 5-Bromo-2-chloro-N-(4-methoxyphenyl)pyrimidin-4-amine (5). The 4-methoxyphenyl amine 4 (150 mmol) was added to a solution of the 5-bromo-2,4-dichloropyrimidine 3 (100 mmol) in i-PrOH (200 mL) at ambient temperature. The rst batch of precipitant appeared aer a few minutes of stirring at r.t. Aer ltration, to the ltrate was added the solution of K 2 CO 3 (300 mmol) in water (200 mL), and the reaction mixture was stirred at room temperature until all of the 5-bromo-2,4-dichloropyrimidine 3 was consumed completely by TLC monitoring. The resulting second batch of precipitant was ltered and the lter cake was washed with water and ethyl acetate in sequence. Aer desiccation, the two batches of precipitant were combined to gain the 5-bromo-2-chloro-N-phenylpyrimidin-4-amines 5 as a gray solid (16.17 a radiochemical yield of 9-16% (decay not corrected), respectively. The radiochemical purity of all tracers was greater than 98%.
Octanol/water partition coefficient
The radioactivity of the n-octanol layer and that of the PBS layer for [ 18 F]2 and [ 18 F]3 were measured as previously described in our recent work: 22 we added a 0.1 mL solution of each of the radiotracers (370 KBq, 10 mCi) in normal saline to a tube containing 0.9 mL of phosphate-buffered saline (0.05 M, PBS, pH 7.4) and 1.0 mL of n-octanol (each phase had been presaturated with the opposite phase overnight before use). The mixture was vortexed for 0.5-1.0 min and centrifuged at 5000 rpm for 5 min. Aliquots of both phases were transferred in triplicate with micropipettes to counting tubes and were assayed in a gcounter aer standing for a while. Then, the partition coefficient was calculated by dividing the radioactivity of the n-octanol layer with that of the PBS layer. This measurement was repeated three times.
Stability test in vitro
The stability test in vitro of the radiotracers were performed following the procedure in our previous report:
22 each of the radiotracers (370 KBq, 10 mCi) puried by the HPLC in 100 mL of normal saline was mixed with 500 mL of normal saline at 37 C for 1 h and 2 h, respectively. Approximately 0.1 mL of the solution was analyzed by radio-HPLC (about the HPLC analysis condition, please refer to the above Section 2.1).
The stability of each HPLC-puried radiotracer in mouse plasma was determined by incubating 100 mL of radiotracer (370 KBq, 10 mCi) in the solution of 500 mL murine plasma at 37 C for 1 h and 2 h, respectively. Plasma proteins were precipitated by adding 200 mL of acetonitrile aer centrifugation at 5000 rpm for 5 min at 4 C. About 100 mL of the supernatant part was injected into radio-HPLC. Before the compound testing, the optimization of the concentration of the enzyme used in the assay, as well as the enzymatic reaction time and the ATP concentration was performed.
Phosphorylation of the TK substrate-biotin was challenged with serially diluted compounds at 1/2-log concentrations starting at a top concentration of 100 mM (which was the nal concentration for the enzymatic step (10 mL)). Each concentration was tested in triplicate.
During enzymatic reaction step, 4 mL compounds in kinase buffer and 2 mL TK substrate-biotin were incubated with 2 mL kinase in kinase buffer and 2 mL ATP in kinase buffer (with the above optimized concentration) was added to start the enzymatic reaction. The mixture was incubated for the above optimized time at room temperature.
The detection reagents [5 mL Eu 3+ -cryptate labeled TKantibody in HTRF® detection buffer, and 5 mL steptavidin-XL665 in HTRF® detection buffer (0.125 mM, which was the nal concentration for the assay (20 mL))] were mixed and added to the reaction system. The TR-FRET signal was proportional to the phosphorylation level and was detected by a plate reader (BMG FS) aer being incubated for one hour. For each compound, the determination of the IC 50 value was from a sigmoid dose-response curve using Graph-Pad Prism (GraphPad Soware, San Diego, CA, USA). 2.6.2. Building of the S180 tumor bearing mice model and the identication of the expression level of FAK in S180 tumor. First, the animal model of the S180 tumor bearing mice was built following the procedure in the literature:
22 the S180 sarcoma cell suspension was made of the ascites transferred from a sacriced S180 ascites sarcoma mouse, and was diluted four times by the normal saline before use. Next, we inoculated the normal ICR mice subcutaneously into the right front ank with the diluted ascites sarcoma cell suspension (0.1 mL per mouse, containing approximately 5 Â 10 6 tumor cells by cell count). It would take about one week for the tumors to reach a size of 0.5-0.8 cm in diameter before the in vivo biodistribution studies could be conducted. Then, sixty pieces of tumor tissue slices (about 4 mm) from sixty S180 tumor bearing mice, and sixty pieces of normal muscle tissue slices (about 4 mm) from sixty normal mice, were used for immunohistochemistry for the identication of the expression level of FAK in S180 tumor.
For the immunohistochemistry, the working concentration of the FAK monoclonal antibody (purchased from Santa Cruz Biotechnology Co., LTd.) was 1 : 40, and the working concentration of the phospho-FAK (pY397FAK) polyclonal antibody (purchased from Upstate Bio technology Co., LTd.) was 1 : 800.
The ready-to-use UltraSensitive™ SP kit (SP9000), the sensitizer DAB (diaminobenzidine) and the HE (hematoxylineosin) staining kit were purchased from Beijing Zhongshan company.
All the tumor tissue slices and normal muscle tissue slices were carried out for HE staining and immunohistochemical staining, with PBS instead of the FAK monoclonal antibody and the pY397FAK polyclonal antibody as the negative control. And the detailed procedures of the immunohistochemistry were according to the SP kit instructions.
The criteria of immunohistochemical results could be divided into four kinds of levels according to the rate of the FAKpositive/pY397FAK-positive cell and the intensity of the staining reaction of the tissue spices: (1) "negative (À)" means that the cell of the tissue slices were not stained, or the rate of the FAKpositive/pY397FAK-positive cell was lower than 25%; (2) "weak positive (+)" means that the cell of the tissue slices were stained as brown yellow, or the rate of the FAK-positive/pY397FAK-positive cell was between 25% and 50%; (3) "moderate positive (++)" means that the cell of the tissue slices were stained as pale yellow, or the rate of the FAK-positive/pY397FAK-positive cell was between 51% and 75%; (4) "strong positive (+++)" means that the cell of the tissue slices were stained as brown, or the rate of the FAK-positive/pY397FAK-positive cell was higher than 75%.
2.6.3. In vivo studies in mice bearing S180 tumor. The in vivo biodistribution study & micro-PET imaging study & blocking study were carried out following the procedure in the literature: 22 Each of the S180 tumor bearing mice was injected via the tail vein with a normal saline solution containing the 18 F-labeled tracers (370 KBq per 100 mL). At 5, 15, 30, 60 and 120 min post injection, ve mice for each time point were sacriced by decapitation. The tissues and organs of interest were immediately collected, weighed and measured for 18 F radioactivity in an automatic gamma counter. The percent dose per gram of wet tissue was calculated by a comparison of the tissue counts to suitably diluted aliquots of the injected material. The values were expressed as mean AE SD (n ¼ 5). For Micro-PET imaging study, the S180 tumor bearing mouse was injected intravenously with approximately 3.7 MBq of [
18 F]2 in 300 mL normal saline, anesthetized with 1.5% isourane in air (about 1.5 mL min
À1
) and xed near the center of Micro-PET scanner with prone position. Static scans (for 30 min, 10 min scan) were obtained on a Siemens Inveon DPET 120. Then, the images were reconstructed and the images were exported.
For blocking studies in the in vivo biodistribution and micro-PET imaging studies, at one hour prior to the injection of the radiotracer [
18 F]1, a group of mice received PF-562271 in 5%
Gelucire 44/14 in sterile water (Gattefosse) (dose: 33 mg kg À1 , p.o.).
Computational chemistry
The structure of the NVP-TAE226 (the chemical structure of it was shown in the Section 2.5 of our previous report 22 ), which was in the complex with FAK (the RCSB Protein Data Bank (PDB) deposition number of the X-ray single-crystal diffraction structures: 2JKK), was selected as the molecular template for sketching the structures of the F-19 standards in this work. For each of the compounds, the conformations resulting from molecular docking, were obtained via the previous structure sketching, molecular energy minimization, systematic conformational search using the Sybyl-X 1.3 molecular modeling soware package (Tripos Associates, St. Louis, MO), AM1 optimization on Gaussian 09 and the molecular docking into the ATP binding site of FAK based on 2JKK.pdb with AutoDock 4.0. The results of the docking studies were viewed with the Sybyl-X 1.3.
The conformations resulting from molecular docking were served as the initial conformations of ligands for the MD simulations, and the subsequent MD simulations were also undertaken following the protocols in the Section 4.8 of the literature. Fig. 1) , respectively, using analytical HPLC conditions described in the Section 2.1. Specic activity, estimated by comparing the UV peak intensity of puried F-18 labeled compounds with reference nonradioactive compounds, ranged from 34 to 52 GBq mmol À1 at the end of synthesis.
In vitro stability study
It could be seen from the radio-HPLC analysis that all the radiotracers were stable in both normal saline and murine plasma at 37 C aer 1 h and 2 h (Fig. S1 ) (see the ESI †). We chose two solvent conditions -normal saline and murine plasma in the in vitro stability study for the following reasons: rst, since the radiotracers were injected into the body as a normal saline solution, their stability in normal saline should be observed. What's more, their in vitro stability in murine plasma should also be determined, because we oen use mice as the primary animal model to carry out the in vivo biological evaluation. Therefore, if the radiotracers were not stable even in the murine plasma, they would be unstable aer being injected into the blood of the mice and won't effectively reach the target organ. So the following biological evaluation would be meaningless. an good selectivity prole against the tested kinases, with 62.4 folds selectivity against PYK2, 75.5 folds selectivity against EGFR, and more than 200 folds selectivity against IGF-1R and PDGFRb, which were also even better than the results in our published work. (Fig. 2) , while most of the normal muscle cells are not stained or just weakly stained. The moderate and strong positive expression rates of FAK and pY397FAK in sixty S180 tumor tissues (58.3% and 40.0% respectively) were signicantly higher than those in sixty normal muscle tissues (11.7% and 6.7% respectively), with statistical signicance (P < 0.05) ( Table 3 ). This suggested that the FAK was highly expressed or over-expressed in S180 tumor tissue.
3.4.3. In vivo biodistribution studies in S180-tumorbearing mice. It could be concluded from Tables S1-S3 (see the ESI †) that as following:
(1) The uptake of all of the three F-18 labeled compounds in tumor, accumulated to their respective high levels at 15 min post-injection (3.69 AE 0.51, 5.40 AE 0.12 and 2.80 AE 0. 33 ted to decline at 60 min post-injection and 120 min postinjection. However, for all the three tracers, their retention in tumor was relatively long, because the radioactivity was still more than half of the peak value at 120 minutes post-injection (3.11 AE 0.22, 3.86 AE 0.14 and 2.88 AE 0.44 % ID per g for [ . And all the three radiotracers showed moderate clearance from blood and metabolism in kidney, which were conclude from the uptake of the three radiotracers in the blood and kidney from 5 min post-injection to 120 min post-injection.
(2) Not only did the length of the FPEG chain has a signi-cant effect on the interaction between the F-19 standards in this work ([ 18 F]1-[ 18 F]3) (expressed as the in vitro inhibitory abilities of enzymatic activities of FAK in this article) and the FAK at the molecular level, but also it played a vital role in the Fig. 1 The HPLC chromatogram of F-18 labeled radiotracers and the corresponding F-19 standards. The HPLC profile data were exported from the *.lcd files by Shimadzu LCSolution Software and were graphically interpreted and coordinate translated by Origin 8.0. From the above analysis, it could be obtained that in order to further increase the uptake of the F-18 labeled tracer in tumor, the following properties of compounds should be improved: (1) the F-18 labeled tumor radiotracers which have closer interaction with the FAK (namely the stronger FAK inhibitory activity) should be further designed in the future. For example, we should build 3D-QSAR models with the experimental FAK IC 50 data of the reported FAK inhibitors to make reasonable guidance for our drug design and quantitatively predict the FAK IC 50 values of the molecular designed by us. What's more, some functional groups which have hydrogen-bonding or salt-bridge interactions with the key residues such as Asp564, Lys454 and Glu506 in the kinase domain of FAK, should be considered to improve the interaction of the drug molecules with the FAK; (2) in this work, the different speed of clearance from the lung affected the uptake of the radiotracers in tumor. This suggested that the F-18 radiotracers with better pharmacokinetic properties should be designed to improve uptake of the radiotracers in tumor and the speed of clearance from the non-target organs. Dynamic drug absorption and distribution model in different tissues (such as liver, blood, liver, tumor etc.) should be made. The general approach in pharmacokinetic and drug design studies, include calculation of many physical properties about pharmacokinetic properties (such as fat and water partition coefficient -log P, dipole moment, apparent volume of distribution -V d , time to peak -T max , etc.) from the relevant data of the reported hundreds of small molecular tumor imaging agents, linear tting of the physical properties to make the dynamic drug absorption and building of the distribution equation in different tissues. Then, we could use these equations to predict whether the molecules Fig. 2 An example of strong positive FAK and pY397FAK staining in S180 tumor tissue slices (SP Â200). have ideal absorption in tumor and low uptake in non-target tissues, on the basis of the small molecules which have strong interaction with the FAK. These need to take a lot of work, and the relevant study is being carried out by our group. Fig. 3A . In consistent with the above biodistribution results, relatively high tracer uptake in tumor (pointed to by the arrowhead) in the right front ank was observed at 30 min post-injection, while no accumulation in the le front ank was found. The imaging results clearly conrmed that [ 18 F]1 could be accumulated in tumor at 30 min post-injection, which was better than the results of the imaging study in our previous report. 23 In addition, at 30 min post-injection, the activity in bladder, kidney and intestine, was also obvious, which was due to the metabolism in kidney and intestine (since the mice were xed near the center of micro-PET scanner with prone position, but the mice were inoculated subcutaneously into the "right front ank" in the supine position with the diluted ascites sarcoma cell suspension. Therefore, we called the "le front ank" seen from the Fig. 3 as the "right front ank" from the supine position is this work).
What's more, Fig. 3B (blocking study) showed signicantly reduced uptake of the radiotracer in the tumor tissue at 30 min post-injection in mice that received PF-562271 (the positive control drug) at one hour before the injection of radiotracer. Therefore, the micro-PET imaging study, in combination with the results of the above kinase proling assay and our biodistribution data, indicated that the uptake of [ 18 
MD simulations and docking studies
In this section, the molecular dynamics (MD) simulations were applied to further understand the changing trends of the interaction between the different F-19 standards and the FAK, and the uptake of the corresponding F-18 labeled tracers in tumor theoretically, in view of the fact that the MD simulations were carried out with taking the solvent effect on the conformational transitions of the complexes (be comprised of ligands such as the F-19 standards in this work and receptors such as FAK in this study) into full consideration, while the simple docking analysis ignored both the exibility of the proteins (receptors) and the effect of solvation in water. First of all, the rationality of the MD simulations and the validity of the molecular conformation that was used as the initial conformation for the MD simulations, were proved, according to the Section 2.5 in our previous work.
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Then, we undertook the 40 ns MD simulations for all of the three F-19 standards in this work. It could be concluded from the Fig. 4 that, aer equilibration, the RMSD values between the initial conformation and the one during the MD simulation for most of the complexes and ligands were less than 2.0Å. In addition, the stronger the FAK inhibitory activity the F-19 standard had, the stronger the interaction between the F-19 standard and the FAK, the easier the complex system would enter into a state of equilibrium. Table 4 lists the components of molecular mechanics and solvation energies. The mean value of electrostatic energy (DE eletrostatic + DDG PB ) was 27.3 kcal mol À1 with an root-meansquare deviation of 1.6 kcal mol À1 . For the van der Waals and hydrophobic interaction energies (DE vdW + DDG SA ), the mean value was À56.5 with an root-mean-square deviation of 2.1 kcal mol À1 . The entropy (TDS) had the a root-mean-square Fig. 4 The root-mean-square deviations (RMSD) between the starting conformations and the ones during the MD simulation as a function of the simulation time, for the complex (red) and the ligand (blue) in the complexes respectively, which were calculated with the ptraj module of Amber 10 and graphically interpreted by Origin 8.0. The MD simulation production phase was undertaken for 40 ns with a 2 ps time step, namely, 20 000 snapshots in sum. The calculating time for the MD simulation for each compound was about one month on the basis of our current computer cluster condition. 50 , where R was ideal gas constant, T was the temperature in kelvin (298 K was used in this work), and C enzyme was the concentration of enzyme, which was a very small number aer equilibration and could be omitted in most cases.
closer interaction with the FAK (namely the stronger FAK inhibitory activity) should be further designed, via building of models such as 3D-QSAR model to make reasonable guidance for our drug design, and consideration of some functional groups which have hydrogen-bonding or salt-bridge interactions with key residues in the kinase domain of FAK; (2) the F-18 radiotracers with better pharmacokinetic properties should be designed to improve uptake of the radiotracers in tumor and the speed of clearance from the non-target tissues. Dynamic drug absorption and distribution model in different tissues (such as liver, blood, lung, tumor, etc.) should be built, to predict whether the molecules have ideal absorption in tumor and low uptake in non-target tissues, on the basis of the small molecules which have strong interaction with the FAK. The relevant study is being undertaken. These enlightenment may be useful guidance for us to develop better radiotracers for the early diagnosis of cancer.
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